Investigating infections caused by antibiotic-resistant bacteria in a Swiss hospital
Official title: Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital
Run by University Hospital, Basel, Switzerland · NCT04098133 · Data updated 2026-11-12
This study looks at how often antibiotic-resistant bacteria cause infections in patients at a Swiss hospital to see how they can better manage these tough infections.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel) |
| Status | Recruiting |
| Started | August 22, 2019 |
| Main results expected | June 30, 2029 |
| Study ends | June 30, 2029 |
| Registry record updated | June 8, 2026 |
| Trial ID | NCT04098133 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients who have been diagnosed with Carbapenemase-producing bacteria from January 1, 2008, to December 31, 2028.
✕Probably not a fit
Patients who have refused the use of their data for research purposes will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to analyze the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel. It will collect retrospective and prospective data on the time to detection of CPB, initiation of infection control measures, and associated risk factors, including previous antibiotic use. The study will also evaluate patient outcomes related to these infections, providing valuable insights into the management of antibiotic resistance in clinical settings.
Why it matters
Potential benefit: If successful, this study could improve infection control practices and treatment strategies for patients with antibiotic-resistant infections.
How similar studies have gone: Other studies have shown success in understanding antibiotic resistance patterns, making this approach relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028 Exclusion Criteria: * Patients with documented refusal of subsequent use of their data
Where it's running
-
Division of Infectious Diseases and Hospital Epidemiology
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Sarah Tschudin Sutter, Prof. Dr. MD — University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology
- Study coordinator: Sarah Tschudin Sutter, Prof. Dr. MD
- Email: sarah.tschudin@usb.ch
- Phone: +41 61 328 68 10
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.